Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Chilean Safety Association (ACHS) | UNKNOWN |
Not provided
Not provided
Not provided
Not provided
The present study seeks to follow up the cohort of adults representative of Chile's urban population whose levels of chronic pain were evaluated in March 2023 (baseline) as part of the Mental Health Thermometer (MHT) study. The study consists of a 12 month follow-up telephone interview to assess parameters of chronic pain (CP) and subtypes, mental and physical health, lifestyle and adversity and work characteristics.
The study objectives are as follows:
I. Aims of the study:
II. Design:
The design is longitudinal prospective and involves following up the same group of participants from the MHT study to monitor their mental health and CP parameters.
III. Study variables include:
3.1. Main outcome measures (instrument): Presence of chronic pain in the last 3 months, Severity of chronic pain (Chronic pain grade questionnaire; CPG), chronic pain interference in daily activities, social activities and work (CPG), depression (Patient Health Questionnaire; PHQ-9), anxiety (General Anxiety Disorder (GAD-7) 3.2. Secondary outcome measures: chronic pain management strategies, migraine disability (Migraine Disability Assessment, MIDAS), neuropathic pain (Neuropathic pain DN4 Questionnaire; DN4), fibromyalgia (Fibromyalgia Survey Questionnaire; FSQ), insomnia (Insomnia Severity Index; ISI), loneliness (3-item UCLA Loneliness Scale; R-UCLA) 3.3. Variables of interest: job-relates stress (Copenhagen Burnout Inventory; CBI), childhood adversity (Adverse childhood experiences; ACE), negative life events.
IV. Groups:
For the longitudinal analysis, participants will be classified into four groups:
V. Analysis plan:
5.1. Cross-sectional analysis (at follow-up)
5.2. Longitudinal analysis (baseline and follow-up)
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Longitudinal analysis group 1 (no pain) | Participants (general population residing in urban areas of Chile aged 18 years or more) not reporting chronic pain in march 2023 or march 2024 | ||
| Longitudinal analysis group 2 (incident chronic pain) | Participants (general population residing in urban areas of Chile aged 18 years or more) not reporting chronic pain in march 2023 but reporting chronic pain in march 2024 | ||
| Longitudinal analysis group 3 (remitted chronic pain) | Participants (general population residing in urban areas of Chile aged 18 years or more) reporting chronic pain in march 2023 but not reporting it in march 2024 | ||
| Longitudinal analysis group 4 (chronic pain at follow up) | Participants (general population residing in urban areas of Chile aged 18 years or more) reporting chronic pain in march 2023 and march 2024 |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Chronic pain (past 3 months) | Participants will be asked "Have you had constant or frequent pain [most of the day] during the past 3 months?" and asked to identify the average and maximum intensity of pain in that period using a visual analogue scale (VAS) from 0 to 10. Only participants with an average pain of 4 or more will be classified as having significant chronic pain. | Baseline and 12-month follow-up |
| Depression (2 weeks) | As measured by the Patient Health Questionnaire (PHQ-9). Total scores on the PHQ-9 range from 0 to 27 and higher scores indicate higher symptoms of depression. | Baseline and 12-month follow-up |
| Anxiety (2 weeks) | As measured by the General Anxiety Disorder (GAD-7). Total scores on the GAD-7 range from 0 to 21 and higher scores indicate higher symptoms of anxiety. | Baseline and 12-month follow-up |
| Measure | Description | Time Frame |
|---|---|---|
| Migraine Disability | As measured by the MIDAS (Migraine Disability Assessment). Total scores on the MIDAS range from 0 to 20 and higher scores indicate higher disability. | 12-month follow-up |
| Neuropathic Pain |
Not provided
Inclusion Criteria:
Not provided
Not provided
Not provided
Community survey in Chile
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Antonia Errazuriz, PhD | Pontificia Universidad Catolica de Chile | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Pontificia Universidad Catolica de Chile | Santiago | RM | 7550139 | Chile |
The anonymized database and codebook will be made available to researcher in the Dataverse website
Upon first manuscript submission
For researchers
Not provided
Not provided
| ID | Term |
|---|---|
| D059350 | Chronic Pain |
| D009437 | Neuralgia |
| D005356 | Fibromyalgia |
| D003863 | Depression |
| D001008 | Anxiety Disorders |
| D016728 | Self-Injurious Behavior |
| D007319 | Sleep Initiation and Maintenance Disorders |
| ID | Term |
|---|---|
| D010146 | Pain |
| D009461 | Neurologic Manifestations |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided
Not provided
Not provided
Not provided
As measured by the DN4 (Neuropathic pain DN4 Questionnaire). Total scores on the DN4 range from 0 to 10 and Scores ≥ 4/10 indicate neuropathic pain.
| Baseline and 12-month follow-up |
| Fibromyalgia | As measured by the Fibromyalgia Survey Questionnaire (FSQ). The possible score ranges from 0 to 31 points. A score equal to or greater than 13 points is consistent with a diagnosis of fibromyalgia. | 12-month follow-up |
| Self harm (2 weeks) | As measured by item 9 (Thoughts that you would be better off dead or of hurting yourself in some way) of the Patient Health Questionnaire (PHQ-9). | Baseline and 12-month follow-up |
| Insomnia (2 weeks) | As measured by the Insomnia Severity Index (ISI). Responses can range from 0 to 4, where higher scores indicate more acute symptoms of insomnia. | Baseline and 12-month follow-up |
| Loneliness | As measured by the 3-item University of California, Los Angeles Loneliness Scale (R-UCLA). Total scores range from 3 to 9 and higher scores indicate higher perceived loneliness. | Baseline and 12-month follow-up |
| D010523 | Peripheral Nervous System Diseases |
| D009468 | Neuromuscular Diseases |
| D009422 | Nervous System Diseases |
| D009135 | Muscular Diseases |
| D009140 | Musculoskeletal Diseases |
| D012216 | Rheumatic Diseases |
| D001526 | Behavioral Symptoms |
| D001519 | Behavior |
| D001523 | Mental Disorders |
| D020919 | Sleep Disorders, Intrinsic |
| D020920 | Dyssomnias |
| D012893 | Sleep Wake Disorders |